4th Quarter - Report

SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING for SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$60,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
4th Quarter - Report (this page) Jan 11, 2017 $60,000 Replaced
4th Quarter - Amendment Jan 11, 2017 $60,000 Yes

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

The 21st Century Cures Act(HR 6) generally; and the creation of a new imaging drug approval pathway at the FDA specifically. Issues relating to a proposal at the Veterans Administration changing the practice of advanced nursing as it relates to imaging.

LobbyistCovered position, as disclosed
CAITLIN BLAKE KUBLER —

Contacted: Veterans Affairs, Dept of (VA); HOUSE OF REPRESENTATIVES; Energy, Dept of; Office of Science & Technology Policy (OSTP); Centers For Medicare and Medicaid Services (CMS); SENATE; Nuclear Regulatory Commission (NRC); Food & Drug Administration (FDA)

Bills named: H.R. 6 (114th)

Medicare/Medicaid MMM

Nuclear medicine reimbursement generally and nuclear medicine APC's under HOPPS and appropriate use criteria under the MPFS specifically.

LobbyistCovered position, as disclosed
CAITLIN BLAKE KUBLER —

Contacted: SENATE; Food & Drug Administration (FDA); Veterans Affairs, Dept of (VA); Nuclear Regulatory Commission (NRC); Centers For Medicare and Medicaid Services (CMS); Office of Science & Technology Policy (OSTP); HOUSE OF REPRESENTATIVES; Energy, Dept of

Energy/Nuclear ENG

Domestic isotope supply issues generally, including oversight of the American Medical Isotope Production Act of 2011. Medical radiation issues generally, including Nuclear Regulatory Commission regulations.

LobbyistCovered position, as disclosed
CAITLIN BLAKE KUBLER —

Contacted: Veterans Affairs, Dept of (VA); HOUSE OF REPRESENTATIVES; Office of Science & Technology Policy (OSTP); Nuclear Regulatory Commission (NRC); Energy, Dept of; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); SENATE

Pharmacy PHA

Implementation of the radiopharmaceutical provisions of The Drug Quality and Security Act as it relates to compounding.

LobbyistCovered position, as disclosed
CAITLIN BLAKE KUBLER —

Contacted: Office of Science & Technology Policy (OSTP); Centers For Medicare and Medicaid Services (CMS); Veterans Affairs, Dept of (VA); Energy, Dept of; HOUSE OF REPRESENTATIVES; Nuclear Regulatory Commission (NRC); Food & Drug Administration (FDA); SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.